Safetyome and specialized panels for over 3,000 phenotypes: a systematic and translational approach using human genetics and pharmacology
Open accessThe DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Abstract
Drug candidates are often evaluated for their activities against unexpected targets (off-targets), to either prospectively flag potential hazards or to provide mechanistic insights for a given phenotype. The in vitro to in vivo translatability is critical when selecting which "phenotypically consequential" off-targets to screen. To this end, human genetics and indication-based pharmacology offer unraveled insights. Enhanced natural language processing tools were applied to harness the power of large data obtained from 7 genetics and 2 pharmacology databases. Mapping biological roles to organ systems, we curated targets implicated in 22 organ systems of safety concerns, resulting in a safetyome composed of over ∼11,000 proteins. This is a significant expansion from our previously proposed screen, whose scope included phenotypes affecting 5 organ systems. Prioritization of the large panel using expression pattern and gene conservation across species resulted in a core panel of 500 targets. Mapping biological roles obtained from the databases to specific terms allowed us to systematically generate over 3,000 phenotype-based (specialized) panels, which can be used as gene or protein sets for issue resolution. All three components: The full safetyome, the core panel of 500 targets, and the over 3,000+ specialized panels, were systematically and orthogonally tested using independent data source, i.e., gene expression data from the Comparative Toxicogenomics Database. All panels, together with a user-friendly App, are published to aid effective safety assessment and issue resolution with strong "translational" focus.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“a Safetyome tool, a curated resource centered on drug safety–critical genes/proteins and their associated AEs.”
From A large-scale concordance study of toxicity findings across preclinical species and humans for small molecules and biologics (2026) · cites this paper as Liu et al., 2026
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
clusterProfiler: an R Package for Comparing Biological Themes Among Gene Clusters
Yu, G., Wang, L.-G., Han, Y., & He, Q.-Y. (2012) · OMICS: A Journal of Integrative Biology · doi:10.1089/omi.2011.0118 · Cited by 36,259
clusterProfiler 4.0: A universal enrichment tool for interpreting omics data
(2021) · doi:10.1016/j.xinn.2021.100141 · Cited by 12,455
DrugBank 5.0: a major update to the DrugBank database for 2018
Wishart, D. S., Feunang, Y. D., Guo, A. C., Lo, E. J., Marcu, A., Grant, J. R., Sajed, T., Johnson, D., Li, C., Sayeeda, Z., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx1037 · Cited by 8,404 · cited 1×
“The pharmacology databases used were DrugBank (DrugBank; Wishart et al. 2018; Knox et al. 2024) and the Therapeutic Target Database (TTD) (Database; Zhou et al. 2024).”
A haplotype map of the human genome
The International HapMap Consortium (2005) · Nature · doi:10.1038/nature04226 · Cited by 5,858
Eslam, M., Newsome, P. N., Sarin, S. K., Anstee, Q. M., Targher, G., Romero-Gomez, M., Zelber-Sagi, S., Wai-Sun Wong, V., Dufour, J.-F., Schattenberg, J. M., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.03.039 · Cited by 4,472
The unified medical language system (UMLS): integrating biomedical terminology
Bodenreider, O. (2004) · Nucleic Acids Research · doi:10.1093/nar/gkh061 · Cited by 4,356
The DisGeNET knowledge platform for disease genomics: 2019 update
Piñero, J., Ramírez-Anguita, J. M., Saüch-Pitarch, J., Ronzano, F., Centeno, E., Sanz, F., & Furlong, L. I. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz1021 · Cited by 2,639 · cited 5×
“(Pinero et al. 2020) indicate that phenotype descriptions concerning rare diseases require improved standardization.”
InfluentialDomain-specific language model pretraining for biomedical natural language processing
Gu, Y., Tinn, R., Cheng, H., Lucas, M., Usuyama, N., Liu, X., Naumann, T., Gao, J., & Poon, H. (2022) · ACM Transactions on Computing for Healthcare · doi:10.1145/3458754 · Cited by 2,170
DrugBank 6.0: the DrugBank Knowledgebase for 2024
Knox, C., Wilson, M., Klinger, C. M., Franklin, M., Oler, E., Wilson, A., Pon, A., Cox, J., Chin, N. E. (., Strawbridge, S. A., et al. (2024) · Nucleic Acids Research · doi:10.1093/nar/gkad976 · Cited by 1,727
The support of human genetic evidence for approved drug indications
Nelson, M. R., Tipney, H., Painter, J. L., Shen, J., Nicoletti, P., Shen, Y., Floratos, A., Sham, P. C., Li, M. J., Wang, J., et al. (2015) · Nature Genetics · doi:10.1038/ng.3314 · Cited by 1,666 · cited 2×
“Targets with genetic associations have higher likelihood to be phenotypically consequential (higher translatability), which was demonstrated by numerous studies (Nelson et al. 2015; Nguyen et al. 2019; Carss et al. 2023).”
ClinVar: improvements to accessing data
Landrum, M. J., Chitipiralla, S., Brown, G. R., Chen, C., Gu, B., Hart, J., Hoffman, D., Jang, W., Kaur, K., Liu, C., et al. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkz972 · Cited by 994
Role of duplicate genes in genetic robustness against null mutations
Gu, Z., Steinmetz, L. M., Gu, X., Scharfe, C., Davis, R. W., & Li, W.-H. (2003) · Nature · doi:10.1038/nature01198 · Cited by 889 · cited 2×
“…which in vivo to in vitro translatability are high, as interfering with a target might have little or no phenotypic manifestation due to the existence of redundant genes or compensatory pathways (Nowak et al. 1997; Gibson and Spring 1998; Gu et al. 2003; Vavouri et al. 2008; Laruson et al. 2020).”
Pe'er, I., Yelensky, R., Altshuler, D., & Daly, M. J. (2008) · Genetic Epidemiology · doi:10.1002/gepi.20303 · Cited by 783
Evolution of genetic redundancy
Nowak, M. A., Boerlijst, M. C., Cooke, J., & Smith, J. M. (1997) · Nature · doi:10.1038/40618 · Cited by 764
Reducing safety-related drug attrition: the use of in vitro pharmacological profiling
Bowes, J., Brown, A. J., Hamon, J., Jarolimek, W., Sridhar, A., Waldron, G., & Whitebread, S. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3845 · Cited by 748 · cited 3×
“The panel typically contains � 70 to 200 off-targets, for which high-throughput in vitro assays are used (Bowes et al. 2012; Whitebread et al. 2016; Jenkinson et al. 2020; Brennan et al. 2024).”
Harrison, P. W., Amode, M. R., Austine-Orimoloye, O., Azov, A. G., Barba, M., Barnes, I., Becker, A., Bennett, R., Berry, A., Bhai, J., et al. (2024) · Nucleic Acids Research · doi:10.1093/nar/gkad1049 · Cited by 742
TTD: Therapeutic Target Database describing target druggability information
Zhou, Y., Zhang, Y., Zhao, D., Yu, X., Shen, X., Zhou, Y., Wang, S., Qiu, Y., Chen, Y., & Zhu, F. (2024) · Nucleic Acids Research · doi:10.1093/nar/gkad751 · Cited by 645
A benchmark of gene expression tissue-specificity metrics
Kryuchkova-Mostacci, N., & Robinson-Rechavi, M. (2016) · Briefings in Bioinformatics · doi:10.1093/bib/bbw008 · Cited by 461
The NHGRI-EBI GWAS Catalog: standards for reusability, sustainability and diversity
Cerezo, M., Sollis, E., Ji, Y., Lewis, E., Abid, A., Bircan, K. O., Hall, P., Hayhurst, J., John, S., Mosaku, A., et al. (2025) · Nucleic Acids Research · doi:10.1093/nar/gkae1070 · Cited by 415
The Human Phenotype Ontology in 2024: phenotypes around the world
Gargano, M. A., Matentzoglu, N., Coleman, B., Addo-Lartey, E. B., Anagnostopoulos, A. V., Anderton, J., Avillach, P., Bagley, A. M., Bakštein, E., Balhoff, J. P., et al. (2024) · Nucleic Acids Research · doi:10.1093/nar/gkad1005 · Cited by 410 · cited 6×
“Similarly, unmapped terms in HPO (11.2”
InfluentialImmune-mediated inflammatory disease therapeutics: past, present and future
McInnes, I. B., & Gravallese, E. M. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-021-00603-1 · Cited by 337
Liver diseases: epidemiology, causes, trends and predictions
Gan, C., Yuan, Y., Shen, H., Gao, J., Kong, X., Che, Z., Guo, Y., Wang, H., Dong, E., & Xiao, J. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02072-z · Cited by 310
Emerging and evolving concepts in gene essentiality
Rancati, G., Moffat, J., Typas, A., & Pavelka, N. (2018) · Nature Reviews Genetics · doi:10.1038/nrg.2017.74 · Cited by 277
The Genotype-Tissue Expression (GTEx) project
Lonsdale, J., Thomas, J., Salvatore, M., Phillips, R., Lo, E., Shad, S., Hasz, R., Walters, G., Garcia, F., Young, N., et al. (2013) · Nature Genetics · doi:10.1038/ng.2653 · Cited by 263 · cited 1×
“Tau index obtained from Genotype-Tissue Expression (GTEx, v8) (Lonsdale et al. 2013; L € uleci and Yılmaz 2022) was used to rank overall tissue specificity in each target as published previously (Palmer et al. 2021).”
Comparative Toxicogenomics Database’s 20th anniversary: update 2025
Davis, A. P., Wiegers, T. C., Sciaky, D., Barkalow, F., Strong, M., Wyatt, B., Wiegers, J., McMorran, R., Abrar, S., & Mattingly, C. J. (2025) · Nucleic Acids Research · doi:10.1093/nar/gkae883 · Cited by 248
Ramos, E. M., Hoffman, D., Junkins, H. A., Maglott, D., Phan, L., Sherry, S. T., Feolo, M., & Hindorff, L. A. (2014) · European Journal of Human Genetics · doi:10.1038/ejhg.2013.96 · Cited by 231
Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery
Buniello, A., Suveges, D., Cruz-Castillo, C., Llinares, M. B., Cornu, H., Lopez, I., Tsukanov, K., Roldán-Romero, J. M., Mehta, C., Fumis, L., et al. (2025) · Nucleic Acids Research · doi:10.1093/nar/gkae1128 · Cited by 217
The importance of genetic redundancy in evolution
Láruson, Á. J., Yeaman, S., & Lotterhos, K. E. (2020) · Trends in Ecology & Evolution · doi:10.1016/j.tree.2020.04.009 · Cited by 201
The interplay of factors in metabolic syndrome: understanding its roots and complexity
Islam, M. S., Wei, P., Suzauddula, M., Nime, I., Feroz, F., Acharjee, M., & Pan, F. (2024) · Molecular Medicine · doi:10.1186/s10020-024-01019-y · Cited by 169
Pleiotropy and Cross-Disorder Genetics Among Psychiatric Disorders
Lee, P. H., Feng, Y.-C. A., & Smoller, J. W. (2021) · Biological Psychiatry · doi:10.1016/j.biopsych.2020.09.026 · Cited by 157
Grissa, D., Junge, A., Oprea, T. I., & Jensen, L. J. (2022) · Database · doi:10.1093/database/baac019 · Cited by 144
ClinVar Miner: Demonstrating utility of a Web-based tool for viewing and filtering ClinVar data
Henrie, A., Hemphill, S. E., Ruiz-Schultz, N., Cushman, B., DiStefano, M. T., Azzariti, D., Harrison, S. M., Rehm, H. L., & Eilbeck, K. (2018) · Human Mutation · doi:10.1002/humu.23555 · Cited by 139
Genetic redundancy in vertebrates: polyploidy and persistence of genes encoding multidomain proteins
Gibson, T. J., & Spring, J. (1998) · Trends in Genetics · doi:10.1016/s0168-9525(97)01367-x · Cited by 134
Widespread conservation of genetic redundancy during a billion years of eukaryotic evolution
Vavouri, T., Semple, J. I., & Lehner, B. (2008) · Trends in Genetics · doi:10.1016/j.tig.2008.08.005 · Cited by 119
Palmer, D., Fabris, F., Doherty, A., Freitas, A. A., & de Magalhães, J. P. (2021) · Aging · doi:10.18632/aging.202648 · Cited by 114
Phenotypes associated with genes encoding drug targets are predictive of clinical trial side effects
Nguyen, P. A., Born, D. A., Deaton, A. M., Nioi, P., & Ward, L. D. (2019) · Nature Communications · doi:10.1038/s41467-019-09407-3 · Cited by 101
Using human genetics to improve safety assessment of therapeutics
Carss, K., Deaton, A. M., Río-Espínola, A. D., Diogo, D., Fielden, M. R., Kulkarni, D. A., Moggs, J. G., Newham, P., Nelson, M. R., Sistare, F. D., et al. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00561-w · Cited by 100
A New Method for the Discovery of Essential Proteins
Zhang, X., Xu, J., & Xiao, W. (2013) · PLoS ONE · doi:10.1371/journal.pone.0058763 · Cited by 94
Papoian, T., Chiu, H.-J., Elayan, I., Jagadeesh, G., Khan, I. A., Laniyonu, A. A., Li, C. X., Saulnier, M., Simpson, N. E., & Yang, B. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd3845-c1 · Cited by 77
The state of the art in secondary pharmacology and its impact on the safety of new medicines
Brennan, R., Jenkinson, S. G., Brown, A. J., Delaunois, A. G., Dumotier, B. M., Pannirselvam, M., Rao, M., Ribeiro, L. R., Schmidt, F., Sibony, A., et al. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-00942-3 · Cited by 70
A practical guide to secondary pharmacology in drug discovery
Jenkinson, S. G., Schmidt, F., Ribeiro, L. R., Delaunois, A. G., & Valentin, J. (2020) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2020.106869 · Cited by 67
Tissue-specific genetic features inform prediction of drug side effects in clinical trials
Duffy, Á., Verbanck, M., Dobbyn, A. L., Won, H., Rein, J. L., Forrest, I. S., Nadkarni, G. N., Rocheleau, G., & Do, R. (2020) · Science Advances · doi:10.1126/sciadv.abb6242 · Cited by 62
Metabolic disorder in Alzheimer’s disease
Poddar, M. K., Banerjee, S., Chakraborty, A., & Dutta, D. (2021) · Metabolic Brain Disease · doi:10.1007/s11011-021-00673-z · Cited by 62
Secondary pharmacology: screening and interpretation of off-target activities – focus on translation
Whitebread, S., Dumotier, B. M., Armstrong, D., Fekete, A., Chen, S., Hartmann, A., Muller, P. Y., & Urbán, L. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.04.021 · Cited by 60
Robust and rigorous identification of tissue-specific genes by statistically extending tau score
Lüleci, H. B., & Yılmaz, A. (2022) · BioData Mining · doi:10.1186/s13040-022-00315-9 · Cited by 54
Papoian, T., Jagadeesh, G., Saulnier, M., Simpson, N. E., Ravindran, A., Yang, B., Laniyonu, A. A., Khan, I. A., & Szarfman, A. (2017) · Toxicologic Pathology · doi:10.1177/0192623317690609 · Cited by 40
Rationalizing Secondary Pharmacology Screening Using Human Genetic and Pharmacological Evidence
Deaton, A. M., Fan, F., Zhang, W., Nguyen, P. A., Ward, L. D., & Nioi, P. (2018) · Toxicological Sciences · doi:10.1093/toxsci/kfy265 · Cited by 29
Clarifying the causes of consistent and inconsistent findings in genetics
Dattani, S., Howard, D. M., Lewis, C. M., & Sham, P. C. (2022) · Genetic Epidemiology · doi:10.1002/gepi.22459 · Cited by 29
Genetic Approach to Evaluation of Hearing Loss
COHEN, M. P., & Phillips, J. A. (2011) · Otolaryngologic Clinics of North America · doi:10.1016/j.otc.2011.08.015 · Cited by 27
Schaafsma, G. C. P., & Vihinen, M. (2017) · Human Mutation · doi:10.1002/humu.23236 · Cited by 25
Liu, X., Zhang, Y., Ward, L. D., Yan, Q., Bohnuud, T., Hernandez, R., Lao, S., Yuan, J., & Fan, F. (2021) · Scientific Reports · doi:10.1038/s41598-021-95354-3 · Cited by 21
Self-citationHuman genetic evidence enriched for side effects of approved drugs
Minikel, E. V., & Nelson, M. R. (2025) · PLoS Genetics · doi:10.1371/journal.pgen.1011638 · Cited by 21
Carey, J. C., & Palumbos, J. C. (2016) · The Indian Journal of Pediatrics · doi:10.1007/s12098-015-1941-x · Cited by 16
Reasons and Resolutions for Inconsistent Variant Interpretation
Lin, L., Pan, H., Qi, Y., Ma, Y., & Qiu, L. (2023) · Human Mutation · doi:10.1155/2023/4955235 · Cited by 16
Verbist, B. M. P., Verheyen, G. R., Vervoort, L., Crabbe, M., Beerens, D., Bosmans, C., Jaensch, S., Osselaer, S., Talloen, W., den Wyngaert, I. V., et al. (2015) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.5b00103 · Cited by 11
Evidence that conserved essential genes are enriched for pro-longevity factors
Oz, N., Vayndorf, E. M., Tsuchiya, M., McLean, S., Turcios-Hernandez, L., Pitt, J. N., Blue, B. W., Muir, M., Kiflezghi, M. G., Tyshkovskiy, A., et al. (2022) · GeroScience · doi:10.1007/s11357-022-00604-5 · Cited by 10
Identification of genetic mechanisms for tissue-specific genetic effects based on CRISPR screens
Dvir, E., Shohat, S., Flint, J., & Shifman, S. (2022) · Genetics · doi:10.1093/genetics/iyac134 · Cited by 10
Diligent use of MedDRA terminology and preferred term selection in safety reports of clinical trials
Fey, M. F., O’Reilly, S., Awada, A. H., Crowley, J. J., & Gelmon, K. A. (2024) · Current Opinion in Oncology · doi:10.1097/cco.0000000000001056 · Cited by 8
Research works printed but not linked: 5
- Bonferroni C. 1936. Teoria statistica delle classi e calcolo delle probabilita. Pubblicazioni Del R Istituto Superiore Di Scienze Economiche e Commericiali Di Firenze. 8: 3– 62.
- Kang Y, Sun Z, Wang S, Huang Z, Wu Z, Ma X. 2021. Metamap: Supporting visual metaphor ideation through multi-dimensional example-based exploration. Paper presented at: Proceedings of the 2021 CHI conference on human factors in computing systems. Yokohama, Japan: Association for Computing Machinery.
- Phenotype-genotype integrator [accessed 2024 July]. https://www.ncbi.nlm.nih.gov/gap/phegeni
- Scispacy: Fast and robust models for biomedical natural language processing. 2019; Florence, Italy: Association for Computational Linguistics.
- Wolf T, Debut L, Sanh V, Chaumond J, Delangue C, Moi A, Cistac P, Rault T, Louf R, Funtowicz M. 2019. Huggingface’s transformers: State-of-the-art natural language processing. arXiv preprint arXiv: 191003771., preprint: not peer reviewed.
Cited by
Liu, X., & Fan, F. (2026) · Frontiers in Toxicology · doi:10.3389/ftox.2026.1731947 · Cited by 4
“The foundational approach for the Safetyome was described previously (Liu et al., 2021; Liu et al., 2026), and has since been further enhanced in our research.”
Metadata
- Authors
- Liu, X., Chen, Y.-W., Xu, X., Smith, D., & Fan, F.
- Affiliations
- Johnson & Johnson (United States) (US)
- Corresponding author
- Fan, Fan
- ORCID
- Liu, Xin
- Venue
- Toxicological Sciences
- Publisher
- Oxford University Press (OUP)
- Published
- 2026-02-19
- Volume
- 209
- Issue
- 3
- ISSN
- 1096-0929 (ISSN-L)
- PMC
- PMC13016935
- OpenAlex
- W7130606267
- Cited by
- 1
- References
- 54
- Citations by year
- 2026: 1
- FWCI
- 3.61
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Toxicological Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Johnson & Johnson
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Health Sciences › Medicine › Health Informatics › Biomedical Text Mining and Ontologies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bioinformatics and Genomic Networks
- Keywords
- off-target screening, drug safety assessment, human genetics, natural language processing, Comparative Toxicogenomics Database, gene expression, drug target prioritization, problem resolution
- MeSH terms
- Biocuration, Animals, Humans, Phenotype, Databases, Factual, Databases, Genetic, Toxicogenetics, Translational Research, Biomedical, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.